Multi-platform biomarkers of response to an immune checkpoint inhibitor in the neoadjuvant I-SPY 2 trial for early-stage breast cancer.

Cell Rep Med · 2024 · PMC11604542 · PMID 39510069

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

nominally significantno p-value reported

In contrast, 10 markers were significantly associated with response to Pembro in HR + HER2 − tumors, with an additional 9 nominally significant markers.

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.